|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02348 DAWNRAYS PHARMA
Nominal 
0.995 0.000 (0.000%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 545,842 | -13.417% | 1,230,867 | 1,060,309 | 1,151,145 | 1,277,682 |
| Cost of Sales | (263,091) | -16.861% | (618,716) | (482,681) | (509,626) | (504,131) |
| Gross Profit | 282,751 | -9.946% | 612,151 | 577,628 | 641,519 | 773,551 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | (3,696) | (40,933) | (61,905) | |
| Profit / (Loss) before Taxation | 158,159 | 21.365% | 249,613 | 636,949 | 414,057 | 438,408 | |
| Taxation | (34,815) | 21.692% | (38,506) | (74,187) | (91,390) | (82,557) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 2,864 | 2,178 | 3,333 | 2,206 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 123,344 | 17.951% | 213,971 | 564,940 | 326,000 | 358,057 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (12,805) | -21.610% | (29,765) | (32,815) | (24,938) | (19,004) |
| Depreciation & Amortisation | 48,789 | 22.922% | 90,956 | 106,623 | 83,893 | 66,410 |
| Directors' Emoluments | -- | -- | -- | 3,031 | 2,973 | 3,089 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 8.200 | 17.799% | 14.000 | 38.000 | 21.740 | 23.890 |
| DPS (cts) | 1.296 | -- | 5.548 | 8.798 | 7.262 | 7.666 |
| Dividend Payout Ratio (%) | 15.808% | -- | 39.629% | 23.153% | 33.405% | 32.087% |
| Cash flow per share ($) | -- | -- | 0.237 | 0.146 | 0.226 | 0.290 |
| NBV per share ($) | 2.278 | -- | 2.252 | 2.213 | 1.903 | 1.763 |
| Remarks: | Real time quote last updated: 11/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 123,344 |
| %Change | 17.951% |
| EPS / (LPS) | RMB 0.082 |
| NBV Per Share (¥) | RMB 2.278 |